Hanley Patrick J
Program for Cell Enhancement and Technologies for Immunotherapy, Division of Blood and Marrow Transplantation, Sheikh Zayed Institute for Pediatric Surgical Innovation, Children's National Health System, The George Washington University, Washington, DC, USA,
Methods Mol Biol. 2015;1283:1-11. doi: 10.1007/7651_2014_175.
With a range of therapeutic uses, from diabetes and Crohn's disease to wound repair, interest in the function, characterization, and expansion of mesenchymal stromal cells (MSCs) is growing rapidly. When considering the therapeutic use of MSCs, one must take into account a multitude of options including the ideal source of MSCs, the ideal donor, and the best means of expansion. Here we discuss different sources of MSCs, including cord blood, bone marrow, and adipose tissue, the option of using autologous and allogeneic donors, and finally we discuss GMP-applicable expansion protocols aimed at expanding MSCs for clinical use.
间充质基质细胞（MSC）具有从糖尿病、克罗恩病到伤口修复等一系列治疗用途，人们对其功能、特性及扩增的兴趣正迅速增长。在考虑MSC的治疗用途时，必须考虑多种选择，包括MSC的理想来源、理想供体以及最佳扩增方法。在此，我们将讨论MSC的不同来源，包括脐带血、骨髓和脂肪组织，使用自体和异体供体的选择，最后我们将讨论旨在扩增用于临床的MSC的符合药品生产质量管理规范（GMP）的扩增方案。
